Leukemia Clinical Trial
Official title:
Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia
The goal of Phase I of this clinical research study is find the highest tolerable dose of
clofarabine that can be given with decitabine, idarubicin, and cytarabine to patients with
acute leukemia.
The goal of Phase II of this study is to learn if decitabine followed by the combination of
clofarabine, idarubicin, and cytarabine can help to control acute leukemia. The safety of
this drug combination will also be studied.
Decitabine and idarubicin are designed to damage the DNA (the genetic material of cells).
This may cause cancer cells to die.
Clofarabine is designed to interfere with the growth and development of cancer cells.
Cytarabine is designed to insert itself into DNA and stop the DNA from repairing itself.
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to a study
group based on when you join this study. Up to 3 groups of 6 participants will be enrolled in
the Phase I portion of the study. Up to 74 participants will be enrolled in Phase II.
Phase I:
If you are enrolled in the Phase I portion, the number of days of clofarabine you receive
will depend on when you joined this study. The first group of participants will receive
clofarabine for 4 days. Each new group will receive clofarabine for the same number of days,
if no intolerable side effects were seen. The number of days may be reduced to 3. The
clofarabine dose per day is the same from group to group.
All participants will receive the same dose level of decitabine, idarubicin and cytarabine.
Phase II:
If you are enrolled in the Phase II portion, you will receive decitabine, idarubicin, and
cytarabine. You will receive clofarabine for the highest number of days that was tolerated in
the Phase I portion.
All participants will receive the same dose level of decitabine, idarubicin, cytarabine, and
clofarabine.
Study Drug Administration:
Each study drug cycle is 33 days. The first cycle of study drugs is called Induction. If the
doctor thinks it is needed, you will have up to 2 Induction cycles.
Phase I (Induction):
On Days 1-5 of each cycle, you will receive decitabine 1 time a day by vein over about 1
hour.
On Days 6-10 of each cycle:
- You will receive cytarabine 1 time a day by vein over about 2 hours.
- On Days 6-8 only, you will receive idarubicin 1 time a day by vein over about 30
minutes.
- You will receive clofarabine 1 time a day by vein over about 1 hour on Days 6-8 or 6-9,
depending on when you join the study.
If the doctor thinks it is needed, your dose level will be reduced after Induction.
If the doctor thinks it is needed, you may receive fewer days of treatment in the Induction
cycle(s).
Phase II (Induction):
On Days 1-5 of each cycle, you will receive decitabine 1 time a day by vein over about 1
hour.
On Days 6-10 of each cycle:
- You will receive cytarabine 1 time a day by vein over about 2 hours.
- On Days 6-8 only, you will receive idarubicin 1 time a day by vein over about 30
minutes.
- You will receive clofarabine 1 time a day by vein over about 1 hour on Days 6-8 or 6-9,
depending on the highest number of days clofarabine was tolerated in the Phase I portion
of the study.
If the doctor thinks it is needed, your dose level will be reduced after Induction.
If the doctor thinks it is needed, you may receive fewer days of treatment in the Induction
cycle(s).
Phases I and II (Consolidation):
If the disease responds to the study drugs, you may receive up to 6 more study drug cycles.
This is called Consolidation.
On Days 1-5 of each cycle:
°You will receive decitabine 1 time a day by vein over 1 hour.
On Days 6-8 of each cycle:
- You will receive cytarabine 1 time a day by vein over about 2 hours.
- You will receive clofarabine 1 time a day by vein over about 1 hour.
- On Days 6-7 only, you will receive idarubicin 1 time a day by vein over about 30
minutes.
If the doctor thinks it is needed, you may receive fewer days of treatment in the
Consolidation cycles.
Study Visits:
Before the start of each cycle, you will have a physical exam, including measurement of your
vital signs.
Every 3-7 days, blood (about 2 teaspoons) will be drawn for routine tests.
On Day 33 of every 2-3 cycles (+/- 7 days), if the doctor thinks it is needed, you will have
a bone marrow aspirate to check the status of the disease. To collect a bone marrow aspirate,
an area of the hip is numbed with anesthetic, and a small amount of bone marrow is withdrawn
through a large needle.
Length of Treatment:
You may continue taking the study drugs for up to 8 cycles. You will no longer be able to
take the study drugs if the disease gets worse, if intolerable side effects occur, or if you
are unable to follow study directions.
Your participation on the study will be over once you have completed the long-term follow-up.
Long-term Follow-up:
Every 3 months for 1 year after your last study drug dose, the study staff will call you and
ask how you are feeling, about any side effects you may be having, and about any other drugs
you may be taking. These calls should last about 5 minutes each.
This is an investigational study. Decitabine is FDA approved and commercially available to
treat myelodysplastic syndrome (MDS). Clofarabine is FDA approved and commercially available
to treat ALL in children. Idarubicin and cytarabine are FDA approved and commercially
available to treat AML. The study drug combination is investigational.
Up to 92 participants will be enrolled in this study. All will take part at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |